Head to Head Survey: Ligand Pharmaceuticals (LGND) vs. The Competition
Ligand Pharmaceuticals (NASDAQ: LGND) is one of 196 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Ligand Pharmaceuticals to similar companies based on the strength of its valuation, risk, analyst recommendations, dividends, profitability, earnings and institutional ownership.
Institutional and Insider Ownership
48.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.7% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Ligand Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Ligand Pharmaceuticals||$117.07 million||$60.55 million||381.04|
|Ligand Pharmaceuticals Competitors||$207.80 million||-$2.20 million||-0.21|
Ligand Pharmaceuticals’ rivals have higher revenue, but lower earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Ligand Pharmaceuticals has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals’ rivals have a beta of 1.63, indicating that their average stock price is 63% more volatile than the S&P 500.
This table compares Ligand Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ligand Pharmaceuticals Competitors||-4,011.43%||-118.67%||-44.00%|
This is a breakdown of recent ratings and target prices for Ligand Pharmaceuticals and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ligand Pharmaceuticals Competitors||797||2965||6485||146||2.58|
Ligand Pharmaceuticals currently has a consensus price target of $137.20, suggesting a potential upside of 0.02%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 4.19%. Given Ligand Pharmaceuticals’ rivals higher possible upside, analysts clearly believe Ligand Pharmaceuticals has less favorable growth aspects than its rivals.
Ligand Pharmaceuticals beats its rivals on 8 of the 13 factors compared.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.
Receive News & Ratings for Ligand Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.